Evidence map›Paper›PMID 38110389›Full record

Observational studyBMJ open2023

Comparing the long-term outcomes in chronic coronary syndrome patients with prior ST-segment and non-ST-segment elevation myocardial infarction: findings from the TIGRIS registry.

Sibi N Krishnamurthy, Stuart Pocock, Prashant Kaul, Ruth Owen, Shaun G Goodman, Christopher B Granger, Jose Carlos Nicolau, Tabassome Simon, Dirk Westermann, Satoshi Yasuda and 5 more

Registry-linked trialOpen access · goldAbstract readMulticenter StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01866904 (TIGRIS), which is not on this map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01866904 terminatednot on this map

TIGRIS: Long-Term rIsk, Clinical manaGement and Healthcare Resource Utilization of Stable Coronary Artery dISease in Post Myocardial Infarction Patients

TypeobservationalSponsorAstraZenecaRan2013 to 2017Enrolled9,284ConditionsStable Coronary Artery Disease (CAD), Myocardial Infarction
3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 27 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 13 institutions in 9 countries.

Sibi N KrishnamurthyCardiovascular Division Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA.
Stuart PocockDepartment of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK.
Prashant KaulInterventional Cardiology, Piedmont Heart Institute, Atlanta, Georgia, USA.
Ruth OwenDepartment of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK.
Shaun G GoodmanDivision of Cardiology, Department of Medicine, Terrence Donnelly Heart Centre, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
Christopher B GrangerDivision of Cardiology, Department of Medicine, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA.
Jose Carlos NicolauInstituto do Coracao (InCor), Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.ORCID 0000-0002-9680-3689
Tabassome SimonDepartment of Clinical Pharmacology, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Paris, France.
Dirk WestermannDepartment of Cardiology and Angiology, University Heart Center Freiburg-Bad Krozingen, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany.
Satoshi YasudaDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan.
Karolina AnderssonAstraZeneca, Gothenburg, Sweden.
Gunnar Brandrup-WognsenAstraZeneca, Gothenburg, Sweden.
Phillip R HuntAstraZeneca, Gaithersburg, Maryland, USA.
David B BriegerConcord Hospital and University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0001-6115-0326
Mauricio G CohenHeart, Vascular & Thoracic Institute, Cleveland Clinic Florida, Weston, Florida, USA cohenm10@ccf.org.ORCID 0000-0003-2038-6070
AstraZeneca (Sweden) · SELondon School of Hygiene & Tropical Medicine · GBAstraZeneca (United States) · USCleveland Clinic Florida · USClinical Research Institute · USHospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · BRNational Cerebral and Cardiovascular Center · JPPiedmont Atlanta Hospital · USSorbonne Université · FRSt. Michael's Hospital · CAThe University of Sydney · AUUniversity of Freiburg · DEUniversity of Miami · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesCompared with ST-segment elevation myocardial infarction (STEMI) patients, non-STEMI (NSTEMI) patients have more comorbidities and extensive coronary artery disease. Contemporary comparative data on the long-term prognosis of stable post-myocardial infarction subtypes are needed.

designLong-Term rIsk, clinical manaGement and healthcare Resource utilisation of stable coronary artery dISease (TIGRIS) was a multinational, observational and longitudinal cohort study.

settingPatients were enrolled from 350 centres, with >95% coming from cardiology practices across 24 countries, from 19 June 2013 to 31 March 2017.

participantsThis study enrolled 8277 stable patients 1-3 years after myocardial infarction with ≥1 additional risk factor. OUTCOME MEASURES: Over a 2 year follow-up, cardiovascular events and deaths and self-reported health using the EuroQol 5-dimension questionnaire score were recorded. Relative risk of clinical events and health resource utilisation in STEMI and NSTEMI patients were compared using multivariable Poisson regression models, adjusting for prognostically relevant patient factors.

resultsOf 7752 patients with known myocardial infarction type, 46% had NSTEMI; NSTEMI patients were older with more comorbidities than STEMI patients. NSTEMI patients had significantly poorer self-reported health and lower prevalence of dual antiplatelet therapy at hospital discharge and at enrolment 1-3 years later. NSTEMI patients had a higher incidence of combined myocardial infarction, stroke and cardiovascular death (5.6% vs 3.9%, p<0.001) and higher all-cause mortality (4.2% vs 2.6%, p<0.001) compared with STEMI patients. Risks were attenuated after adjusting for other patient characteristics. Health resource utilisation was higher in NSTEMI patients, although STEMI patients had more cardiologist visits.

conclusionsPost-NSTEMI chronic coronary syndrome patients had a less favourable risk factor profile, poorer self-reported health and more adverse cardiovascular events during long-term follow-up than individuals post STEMI. Efforts are needed to recognise the risks of stable patients after NSTEMI and optimise secondary prevention and care. TRIAL REGISTRATION NUMBER: NCT01866904.

Indexed as

Coronary Artery DiseaseMyocardial InfarctionNon-ST Elevated Myocardial InfarctionST Elevation Myocardial InfarctionHumansLongitudinal StudiesRegistriesRisk Factorscardiac epidemiologyheart failuremyocardial infarction

Identifiers

PMID38110389
OpenAlexW4389913897

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.